A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
Key RequirementsClinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.
Participants must have a gradual and progressive change in memory or ability to think and function for more than 6 months prior to screening
Participants must have a reliable study partner
Participants Must Not:
Participants must not have significant disease affecting the brain other than Alzheimer's Disease (AD) that could interfere with this study
Participants must not have other serious illnesses that could interfere with this study
Participants must not have a history of severe drug allergies
Participants must not have certain health conditions that prevent them from getting an MRI or positron emission tomography (PET) scan
Participants must not have had recent prior treatment with a drug to remove plaque from the brain
Lilly Trial Alerts
Clinical Trial Resources
Neurodegenerative Disease Research
To learn more about neurodegenerative diseases and clinical trials being carried out in the area, visit our Neurodegenerative Disease Research page.
Clinical Trial Participation: What to Expect
A clinical trial is a scientific study. It helps us learn if a new medicine or treatment works and how it works. Clinical trials can also be called clinical research studies. Learn more about clinical research studies and what to expect when taking part in a clinical trial.
You will complete the questionnaire on another website.YesNo